Swedish Healthtech Stock News

The European market has recently experienced modest gains, bolstered by easing geopolitical tensions and robust corporate earnings, despite pressures from potential U.S. tariffs. In this environment, growth companies with high insider ownership can be particularly attractive as they often demonstrate strong alignment between management and shareholders, potentially leading to focused strategic execution and resilience amid broader market fluctuations.

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Today is shaping up negative for Truecaller AB (publ) ( STO:TRUE B ) shareholders, with the analysts delivering a...

Bokusgruppen AB (publ) ( STO:BOKUS ) stock is about to trade ex-dividend in three days. The ex-dividend date is...

The market seemed underwhelmed by last week's earnings announcement from Nyfosa AB (publ) ( STO:NYF ) despite the...

Investors who take an interest in OXE Marine AB (publ) ( STO:OXE ) should definitely note that the Independent Chairman...

Even if it's not a huge purchase, we think it was good to see that Johan Bergdahl, the Director of Swedencare AB (publ...

It's been a good week for Haypp Group AB (publ) ( STO:HAYPP ) shareholders, because the company has just released its...

Sinch AB (publ) ( STO:SINCH ) just released its latest quarterly results and things are looking bullish. It was overall...

We'd be surprised if Hanza AB (publ) ( STO:HANZA ) shareholders haven't noticed that the Founder, Erik Stenfors...

It looks like Generic Sweden AB ( STO:GENI ) is about to go ex-dividend in the next 3 days. The ex-dividend date is two...

It's been a good week for Loomis AB (publ) ( STO:LOOMIS ) shareholders, because the company has just released its...

Mentice AB (publ) ( STO:MNTC ) missed earnings with its latest first-quarter results, disappointing overly-optimistic...

Hansa Biopharma AB (publ) ( STO:HNSA ) shareholders will have a reason to smile today, with the analysts making...

Investors who take an interest in Meko AB (publ) ( STO:MEKO ) should definitely note that the President & CEO, Pehr...

Some Swedish Orphan Biovitrum AB (publ) ( STO:SOBI ) shareholders may be a little concerned to see that the CEO...

The European market has recently experienced modest gains, with the pan-European STOXX Europe 600 Index reflecting improved sentiment due to easing geopolitical tensions and strong corporate earnings, although concerns over potential U.S. tariffs loom. In this environment of fluctuating market dynamics, identifying small-cap stocks that are potentially undervalued can be crucial for investors seeking opportunities; these stocks often offer unique growth prospects when backed by solid...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

The European market has experienced a volatile yet modestly positive week, with the STOXX Europe 600 Index showing gains amid easing geopolitical tensions and robust corporate earnings. However, looming threats of increased tariffs from the U.S. have introduced uncertainty into the market landscape. In this environment, growth companies with high insider ownership can be appealing as they often exhibit strong alignment between management and shareholder interests, potentially offering...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Infrea AB...

I-Tech AB ( STO:ITECH ) investors will be delighted, with the company turning in some strong numbers with its latest...

ALM Equity AB (publ) ( STO:ALM ) missed earnings with its latest quarterly results, disappointing overly-optimistic...

BioArctic (OM:BIOA B) is back in focus after partner Eisai reported a three month U.S. FDA review extension for Leqembi Iqlik, its once weekly subcutaneous lecanemab injection for early Alzheimer’s disease. See our latest analysis for BioArctic. The latest FDA review extension has come alongside a 1-year total shareholder return of 78.23%, while the 90-day share price return of 3.52% suggests some momentum has held up despite short term pullbacks. If this kind of biotech news has your...

Alimak Group (OM:ALIG) is back on investors’ radar after recent share price pressure, with the stock showing declines over the past month and past 3 months despite positive reported annual revenue and net income growth. See our latest analysis for Alimak Group. Over the past year, Alimak Group’s momentum has cooled, with a 24.4% year to date share price decline and a 13.1% 1 year total shareholder return, even though the 3 year total shareholder return of 55.32% remains well ahead of shorter...